1. Home
  2. MOV vs RIGL Comparison

MOV vs RIGL Comparison

Compare MOV & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MOV
  • RIGL
  • Stock Information
  • Founded
  • MOV 1961
  • RIGL 1996
  • Country
  • MOV United States
  • RIGL United States
  • Employees
  • MOV N/A
  • RIGL N/A
  • Industry
  • MOV Consumer Specialties
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • MOV Consumer Discretionary
  • RIGL Health Care
  • Exchange
  • MOV Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • MOV 339.1M
  • RIGL 335.5M
  • IPO Year
  • MOV 1993
  • RIGL 2000
  • Fundamental
  • Price
  • MOV $18.27
  • RIGL $38.85
  • Analyst Decision
  • MOV Strong Buy
  • RIGL Buy
  • Analyst Count
  • MOV 1
  • RIGL 5
  • Target Price
  • MOV $31.50
  • RIGL $38.20
  • AVG Volume (30 Days)
  • MOV 145.4K
  • RIGL 995.6K
  • Earning Date
  • MOV 08-28-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • MOV 7.66%
  • RIGL N/A
  • EPS Growth
  • MOV N/A
  • RIGL N/A
  • EPS
  • MOV 0.77
  • RIGL 5.43
  • Revenue
  • MOV $655,597,000.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • MOV $0.71
  • RIGL $59.93
  • Revenue Next Year
  • MOV N/A
  • RIGL N/A
  • P/E Ratio
  • MOV $23.68
  • RIGL $7.15
  • Revenue Growth
  • MOV 0.79
  • RIGL 105.62
  • 52 Week Low
  • MOV $12.85
  • RIGL $12.66
  • 52 Week High
  • MOV $24.47
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • MOV 70.66
  • RIGL 68.57
  • Support Level
  • MOV $16.75
  • RIGL $39.00
  • Resistance Level
  • MOV $17.55
  • RIGL $42.08
  • Average True Range (ATR)
  • MOV 0.49
  • RIGL 2.32
  • MACD
  • MOV 0.20
  • RIGL -0.37
  • Stochastic Oscillator
  • MOV 99.42
  • RIGL 53.26

About MOV Movado Group Inc.

Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: